Literature DB >> 408556

[Studies of lysozyme activity in serum, urine and blood smears from patients with haematological diseases].

L Labedzki, G Seché, P Lorbacher.   

Abstract

Lysozyme activity was studied in blood smears, serum, and urine of patients suffering from leukaemia or other haematological diseases. Increased enzyme activity was found in myelocytic, myelomonocytic and monocytic leukaemia and equally in secondary granulocytosis and polycythaemia vera. Reduced rates were found in lymphocytie leukaemia, malignant lymphoma with bone marrow involvement, and myelophthisic conditions. A rise in urinary lysozyme occurred when the serum level exceeded 50 microgram/ml. Abundant activities were found in myelomonocytic and monocytic leukaemias. Using the bacteriolytic method in blood smears, no enzyme activity was demonstrated in cells of acute or chronic lymphocytic leukaemia, in monocytic leukaemia however, almost all cells show strong reaction. In acute myelocytic or myelomonocytic leukaemia, the portion of positive cells changes from case to case depending on the degree of cell differentiation and maturation. In chronic myelocytic leukaemia there was no difference as compared to enzyme activity of myelocytes in bone marrow of control cases. Thus the bacteriolytic demonstration of lysozyme in blood smears may additionally contribute to distinction of different types of blastic leukaemias, and serum lysozyme also may allow more reliable insight into granulocytic and monocytic myelopoiesis than morphologic studies of blood or bone marrow smears can do, e.g. in agranulocytosis and pancytopenia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 408556     DOI: 10.1007/bf01478834

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  38 in total

1.  HISTOCHEMICAL DISTRIBUTION OF LYSOZYME ACTIVITY IN ORGANS OF NORMAL MICE AND RADIATION CHIMERAS.

Authors:  A J SPEECE
Journal:  J Histochem Cytochem       Date:  1964-05       Impact factor: 2.479

2.  Myelomonocytic leukaemia supervening on chronic lymphocytic leukaemia.

Authors:  D Catovsky; D A Galton
Journal:  Lancet       Date:  1971-03-06       Impact factor: 79.321

3.  Immunocytological demonstration of lysozyme (muramidase) in human leukaemic cells.

Authors:  H Asamer; F Schmalzl; H Braunsteiner
Journal:  Br J Haematol       Date:  1971-06       Impact factor: 6.998

4.  Urinary muramidase and renal disease. Correlation with renal histology and implication for the mechanism of enzymuria.

Authors:  J P Hayslett; P E Perillie; S C Finch
Journal:  N Engl J Med       Date:  1968-09-05       Impact factor: 91.245

5.  [Significance of muramidase (lysozyme) determination for the diagnosis of leukemia].

Authors:  H Asamer
Journal:  Dtsch Med Wochenschr       Date:  1971-05-07       Impact factor: 0.628

6.  Muramidase studies in Philadelphia-chromosome-positive and chromosome-negative chronic granulocytic leukemia.

Authors:  P E Perillie; S C Finch
Journal:  N Engl J Med       Date:  1970-08-27       Impact factor: 91.245

7.  Diagnostic value of muramidase (Lysozyme) in acute leukemia and preleukemia.

Authors:  J D Youman; M I Saarni; J W Linman
Journal:  Mayo Clin Proc       Date:  1970-03       Impact factor: 7.616

8.  Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia.

Authors:  F M Muggia; H O Heinemann; M Farhangi; E F Osserman
Journal:  Am J Med       Date:  1969-09       Impact factor: 4.965

9.  Significance of changes in serum muramidase activity in megaloblastic anemia.

Authors:  P E Perillie; S S Kaplan; S C Finch
Journal:  N Engl J Med       Date:  1967-07-06       Impact factor: 91.245

10.  Serum and urinary proteins, lysozyme (muramidase), and renal dysfunction in mono- and myelomonocytic leukemia.

Authors:  W Pruzanski; M E Platts
Journal:  J Clin Invest       Date:  1970-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.